Achieve Life Sciences announces proposed public offering; shares down nearly 13%
Source: SeekingAlpha
2025-06-26 16:12:52 ET
More on Achieve Life Sciences
- Achieve Life Sciences: FDA Approval Not Assured, But Valuation Justifies Risk
- Achieve Life Sciences, Inc. (ACHV) Q1 2025 Earnings Call Transcript
- Achieve Life Sciences targets NDA submission for cytisinicline in June 2025 as open label study hits key milestones
- Seeking Alpha’s Quant Rating on Achieve Life Sciences
- Historical earnings data for Achieve Life Sciences
Read the full article on Seeking Alpha
For further details see:
Achieve Life Sciences announces proposed public offering; shares down nearly 13%
Achieve Life Sciences Inc.
NASDAQ: ACHV
ACHV Trading
-3.31% G/L:
$5.23 Last:
167,464 Volume:
$5.30 Open:
ACHV Latest News
June 02, 2026 08:30:00 am
Achieve Life Sciences Appoints Jeffrey Farrow and Reid Waldman, MD to Board of Directors
May 19, 2026 02:15:00 pm
Achieve Life Sciences Presents Safety Data from 52 Weeks of Continuous Cytisinicline Treatment
ACHV Stock Data
$234,761,887
51,636,968
N/A
28
N/A
Biotechnology & Life Sciences
Healthcare
CA
Bothell
